Page 35 - HSP Annual Report 2022

A digital medical imaging pioneer
Self-branded sales in more than 60 countries
A Taiwan Excellence Award recipient for 7 straight years
Stefan Cheng, chairman & president Medimaging Integrated Solution Inc.
Founded by Dr. Stefan Cheng at the HSP in 2010, Medimaging Integrated Solution Inc. (MiiS) secured a listing on the Taiwan Stock Exchange in June 2022. In addition to integrating the resources of industry, government, academia, and the research community, MiiS sources 95% of the materials needed for its self-developed digital medical products in Taiwan. Its digital medical imaging solutions that comprise diagnostic devices, software, and technical services are now offered mainly overseas: the U.S. accounts for 80% of its revenue, mainland China 6.9%, Taiwan 4.3%, and others 8.8%. MiiS revenue is about evenly divided by sales of self-branded products and those from CDMO services.
An 80% U.S. market share for telemedicine imaging devices; Air Force One’s testament
As attested by many accolades won at home and abroad, MiiS leverages four core technologies— opto-mechatronics system design, AI computing, micro camera lens packaging, and endoscopy—to develop fully integrated digital medical devices applicable to
medical prowess is extended to the U.S., Europe, Saudi Arabia, and Southeast Asia. As such, MiiS has both repaid its home country and made a favorable impact on other corners of the world. Of course, MiiS is equally committed to doing its share in promoting environmental sustainability by taking ESG and climate change action.
Ultimate goal: Make a provider of smart healthcare total solutions
Smart healthcare appears poised to move toward telemedicine, digital care (including home care), and minimally invasive diagnostics and treatment. Governments are also gradually revising and relaxing regulations, health insurance regimes, and market mechanisms. Take the U.S., the most important market for MiiS. The American Medical Association has accepted AI-assisted diagnostics for medical health insurance coverage; the FDA now recommends the use of disposable (single-use) endoscopes to minimize the risk of surgery infection. As such, the emerging smart healthcare market is set to further expand amid an increasingly supportive policy and insurance
telemedicine. To date it has captured 80% of the U.S. market for telemedicine imaging equipment. That devices labeled with the MiiS brand of “horus SCOPE” can be found aboard Air Force One has proven a huge boost to its sales worldwide.
In addition to the sales of horus SCOPE products in more than 60 countries, MiiS has entered into technological cooperation with partners in Japan, the U.S. and Germany. Rewards on this front are nearly 50 invention or design patents secured in Taiwan, the U.S., mainland China, Europe, and Japan. In terms of corporate social responsibility, MiiS is proactive not only to help bring medical services to Taiwan’s remote communities but also to play a role in medical diplomacy. Through global telemedicine, Taiwan’s
environment. In Taiwan, efforts are also being made to place remote healthcare under national health insurance coverage.
Given the aforesaid market trends and policy shifts, MiiS is set to focus future R&D on expanding its product mix. High on the agenda will be making remote and digital healthcare products accessible for home use as well as professional applications and develop disposable endoscopes suitable for different branches of medicine. The ultimate goal is for MiiS to develop into a provider of smart healthcare total solutions and foster a well-rounded healthcare ecosystem going forward.
33
3 Score Success via Innovative Empowerment